Funding for this research was provided by:
National Institutes of Health (R01-AR0703015)
Department of Medicine, University of California, San Francisco (Robert L. Kroc Chair in Rheumatic, Connective Tissue Diseases III)
Article History
Received: 6 October 2022
Accepted: 6 February 2023
First Online: 20 March 2023
Declarations
:
: The study was approved by the Institutional Review Board at the University of California (approval #20-30734). Subjects were consented to this protocol.
: Not applicable, as no individual data is presented.
: ECH serves in a volunteer capacity on the Medical Registry Advisory Board of the International Fibrodysplasia Ossificans Progressiva Association. ECH also serves in a volunteer capacity on the Fibrous Dysplasia Foundation Medical Advisory Board. ECH is a member of the International Clinical Council on FOP. ECH received clinical trials support through his institution from Clementia Pharmaceuticals, an Ipsen Company; and Ultragenyx, Inc., for studies unrelated to this project. These pose no conflicts for this study.